244 related articles for article (PubMed ID: 12787731)
21. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
22. Anti-angiogenic therapies for children with cancer.
André N; Verschuur A; Rossler J; Sterba J
Curr Cancer Drug Targets; 2010 Dec; 10(8):879-89. PubMed ID: 20718702
[TBL] [Abstract][Full Text] [Related]
23. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
24. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.
Kerbel RS; Viloria-Petit A; Klement G; Rak J
Eur J Cancer; 2000 Jun; 36(10):1248-57. PubMed ID: 10882863
[TBL] [Abstract][Full Text] [Related]
25. Microtubule-targeting agents in angiogenesis: where do we stand?
Pasquier E; Honoré S; Braguer D
Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139
[TBL] [Abstract][Full Text] [Related]
26. [Angiogenesis and antiangiogenic cancer therapy].
Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
[TBL] [Abstract][Full Text] [Related]
27. Targeting angiogenesis -- a novel mode in cancer chemoprevention.
Vainio H
Asian Pac J Cancer Prev; 2003; 4(2):83-6. PubMed ID: 12875617
[TBL] [Abstract][Full Text] [Related]
28. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
29. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials.
Rüegg C; Meuwly JY; Driscoll R; Werffeli P; Zaman K; Stupp R
Curr Mol Med; 2003 Dec; 3(8):673-91. PubMed ID: 14682490
[TBL] [Abstract][Full Text] [Related]
30. Ischemic vascular disease and solid cancers: opposing ends of the angiogenic spectrum?
Balasubramanian SP; Reed MW
Med Hypotheses; 2006; 67(6):1317-9. PubMed ID: 16828237
[TBL] [Abstract][Full Text] [Related]
31. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
[TBL] [Abstract][Full Text] [Related]
32. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
33. [Dormant tumors and organs resistant to metastasis after gene transfer: dream and reality of anti-angiogenic gene therapy].
Li H; Dkhissi F; Grenet C; Soria C; Lu H
Therapie; 2001; 56(5):501-10. PubMed ID: 11806286
[TBL] [Abstract][Full Text] [Related]
34. Anti-angiogenic therapy: rationale, challenges and clinical studies.
Longo R; Sarmiento R; Fanelli M; Capaccetti B; Gattuso D; Gasparini G
Angiogenesis; 2002; 5(4):237-56. PubMed ID: 12906317
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of angiogenesis and the angiogenesis/invasion shift.
Bikfalvi A; Moenner M; Javerzat S; North S; Hagedorn M
Biochem Soc Trans; 2011 Dec; 39(6):1560-4. PubMed ID: 22103487
[TBL] [Abstract][Full Text] [Related]
36. Anti-angiogenesis in cancer therapy: Hercules and hydra.
Bellou S; Pentheroudakis G; Murphy C; Fotsis T
Cancer Lett; 2013 Sep; 338(2):219-28. PubMed ID: 23707856
[TBL] [Abstract][Full Text] [Related]
37. Current status and future of anti-angiogenic drugs in lung cancer.
Yan X; Zhao Z; Tang H
Clin Exp Med; 2023 Oct; 23(6):2009-2023. PubMed ID: 36920592
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylases: anti-angiogenic targets in cancer therapy.
Mottet D; Castronovo V
Curr Cancer Drug Targets; 2010 Dec; 10(8):898-913. PubMed ID: 20718701
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.
Gately S; Kerbel R
Prog Exp Tumor Res; 2003; 37():179-92. PubMed ID: 12795055
[TBL] [Abstract][Full Text] [Related]
40. Cancer immunotherapy of targeting angiogenesis.
Hou J; Tian L; Wei Y
Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
